Equities

Chosa Oncology AB

Chosa Oncology AB

Actions
  • Price (SEK)1.04
  • Today's Change0.00 / 0.00%
  • Shares traded22.64k
  • 1 Year change-35.80%
  • Beta--
Data delayed at least 15 minutes, as of May 31 2024.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Chosa Oncology AB, formerly RhoVac AB, is a Sweden-based biotechnology company. The Company specializes on research and development of immunotherapeutic drugs. The Company's business focus is found in the development of vaccines for the treatment of metastatic cancer. Immunotherapy treatment is an important part of the operation where the body's own immune system is used to fight and eliminate cancer cells. The Company's drug candidate is used in combination with surgery or radiotherapy. Its products are iCIP, which is combines the identification of patients that will benefit from cisplatin treatment with the ability to treat them with higher efficacy and less toxicity; LiPlaCis is a liposomal formulation of cisplatin enabling direct delivery of this known agent to tumor sites; and DRP is a multigene mRNA-based Drug-specific Response Predictor built upon a deep systems biology analysis of all transcriptional (RNA) changes in tumor cells in response to a broad range of drug types.

  • Revenue in SEK (TTM)73.00k
  • Net income in SEK-23.94m
  • Incorporated2015
  • Employees--
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunovia AB (publ)1.21m-260.73m64.76m11.00--1.48--53.43-6.06-6.060.02760.96480.007558.2314.96110,181.80-160.93-41.33-194.89-44.24-5,523.76-7,553.76-21,512.13-20,879.292.03--0.1675--37.5536.48-84.09---50.93--
ExpreS2ion Biotech Holding AB7.77m-77.95m65.80m18.00--1.26--8.47-1.56-1.560.15091.020.0821--4.87298,730.80-82.36-63.54-113.92-75.88-132.91-1.94-1,003.55-524.31----0.0055--43.07-0.156122.94--19.90--
Spago Nanomedical AB (publ)1.47m-35.58m65.84m12.00--1.92--44.91-0.3129-0.31290.01130.15250.0324--9.91112,769.20-78.60-20.19-93.27-20.97-5.25---2,426.88-4,853.45----0.00--14.14---7.72------
Klaria Pharma Holding AB (publ)-6.53m-20.10m67.73m5.00--1.90-----0.1847-0.4021-0.06210.2743-0.0794-----1,305,600.00-24.44-37.28-40.23-51.56-------2,077.34---1.870.00---100.00--71.17------
Combigene AB3.70m-35.24m69.11m8.00--0.6758--18.67-1.78-1.780.1875.160.0294--1.27462,765.00-27.99-13.00-29.40-14.58-----951.98-58.77----0.00---79.23268.58-479.27---24.02--
Abera Bioscience AB0.00-12.70m70.16m6.00--7.13-----0.9261-0.92610.000.64070.00----0.00-90.08-79.42-117.23-96.10------------0.00------13.74------
PCI Biotech Holding ASA3.00m-20.38m72.33m7.00--1.85--24.12-0.5443-0.54430.08011.050.0556--0.6848427,142.80-37.78-36.44-41.97-40.14-----679.43-1,055.43----0.0081---37.05-20.7863.13------
Prolight Diagnostics AB (publ)0.00-136.81m72.47m16.00--0.5829-----0.3953-0.39530.000.24880.00----0.00-64.42---84.94--------------0.00-----------13.84--
Pila Pharma AB1.46m-9.93m73.76m1.00--11.07--50.42-0.5304-0.53040.07670.280.1513--6.111,463,020.00-102.68-108.88-122.66-121.45-127.88-42.67-678.73-1,577.64---159.470.104---22.21--62.92------
Chosa Oncology AB73.00k-23.94m73.78m----3.88--1,010.71-1.11-1.110.00180.26840.003--0.013---96.68-51.96-178.66-61.92-----32,798.63-708.47---97.970.00---98.21--28.33------
ViroGates A/S8.78m-19.52m77.01m10.00--3.75--8.77-6.00-6.001.442.080.33440.3163.64573,300.00-74.36-46.58-80.05-52.0977.2077.91-222.40-238.0110.45-19.080.2833---45.0110.98-25.40------
Dextech Medical AB0.00-4.53m78.01m1.00--2.52-----0.2449-0.24490.001.67-----------28.96---29.94------------0.00------12.89--0.412--
Peptonic Medical AB39.05m-45.25m81.38m37.00--0.3277--2.08-0.025-0.0250.02220.03230.41851.425.491,055,432.00-48.49-46.02-61.53-60.8544.3454.26-115.88-139.380.5002-140.410.2084---14.93149.65-15.55--27.15--
Ziccum AB6.64m-20.50m87.62m9.00--6.68--13.21-1.46-1.460.47210.85340.2696--22.01829,375.00-83.29-68.51-106.42-76.47-----308.94-2,598.03----0.0516----75.2025.62---13.45--
Wntresearch AB0.00-35.82m89.72m2.00--2.20-----9.19-9.190.004.700.00----0.00-89.47-100.71-103.70-123.59------------0.00-------5.65------
Sprint Bioscience AB68.36m8.77m89.93m36.0010.263.649.641.320.12560.12560.97910.35381.58--11.452,441,286.0020.29-71.2243.20-113.7180.0662.7512.83-110.22----0.00--60,725.3022.9999.27---26.02--
Data as of May 31 2024. Currency figures normalised to Chosa Oncology AB's reporting currency: Swedish Krona SEK
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.